ZL-1102 / ZAI Lab, Crescendo Biologics - LARVOL DELTA

Zai Lab Announces First Quarter 2025 Financial Results and Recent Corporate Updates (Businesswire) - "ZL-1102 (IL-17 Humabody): Zai Lab has decided to discontinue the global Phase 2 clinical trial of ZL-1102 following a comprehensive review of the data from interim analysis from the first 40 enrolled participants and the subsequent recommendation of the independent Data and Safety Monitoring Board."

Trial termination • Psoriasis

Zai Lab Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Updates (Businesswire) - "ZL-1102 (IL-17 Humabody): Zai Lab to provide interim analysis in the global Phase 2 study in chronic plaque psoriasis in the first half of 2025. ZL-1503 (IL-13/IL-31R): Zai Lab to provide preclinical data update and initiate a global Phase 1 study in moderate-to-severe atopic dermatitis...Seronegative gMG: Zai Lab partner argenx to provide topline results from the Phase 3 ADAPT-SERON study in seronegative gMG. Zai Lab participated in the study in Greater China. Lupus Nephritis (LN): Zai Lab to provide topline results from the Phase 2 study in LN."

New P1 trial • P2 data • P3 data • Preclinical • Atopic Dermatitis • Lupus Nephritis • Myasthenia Gravis • Psoriasis

Zai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis (Businesswire) - "Zai Lab Limited...announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP)....The Phase 2 global clinical trial of ZL-1102 is a randomized, double-blind, vehicle-controlled, dose-ranging study in patients with mild-to-moderate CPP. In this 5-arm trial, approximately 250 patients will receive topical therapy for 16 weeks. The primary endpoint is the proportion of patients achieving modified PASI75, which is at least a 75% reduction in the modified PASI score from baseline, at week 16."

Trial status • Psoriasis

A Phase 2 Study of ZL-1102 in Patients With Chronic Plaque Psoriasis (clinicaltrials.gov) - P2 | N=250 | Recruiting | Sponsor: Zai Lab (Hong Kong), Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Dermatology • Immunology • Psoriasis

Topical application of a novel anti-interleukin-17A antibody fragment penetrates psoriatic skin: Results of a randomised, double-blind, placebo-controlled Phase Ib study. (PubMed, Exp Dermatol) - "Topical ZL-1102 showed good safety, local tolerability and a trend towards improved local PASI; skin penetration was observed without measurable systemic exposure. ACTRN12620000700932."

Journal • P1 data • Dermatology • Immunology • Psoriasis • IL17A